The skin disease Buruli ulcer, caused by Mycobacterium ulcerans, is the third most common
mycobacterial disease after tuberculosis and leprosy and mainly affects remote rural African …

Mycobacterium ulcerans disease (Buruli ulcer) is an important health problem in several
west African countries. It is prevalent in scattered foci around the world, predominantly in …

The role of biofilms in the pathogenesis of mycobacterial diseases remains largely unknown.
Mycobacterium ulcerans, the etiological agent of Buruli ulcer, a disfiguring disease in …

According to recommendations of the 6th WHO Advisory Committee on Buruli ulcer, directly
observed treatment with the combination of rifampin and streptomycin, administered daily for …

Buruli ulcer is a skin disease caused by infection with Mycobacterium ulcerans, which
produces a potent toxin known as mycolactone, thus distinguishing itself from all other …

Antibiotics in Laboratory Medicine has been a mainstay resource for practitioners/providers,
investigators, and pharmaceutical researchers of new anti-infective compounds for the past …

Mycobacterium ulcerans was first identified as the causative agent of Buruli ulcer; this
cutaneous tissue‐destructive process represents the third most important mycobacterial …

Seven antimicrobials were tested in vitro against 29 clinical isolates of Mycobacterium
ulcerans. R207910 demonstrated the lowest MIC50 and MIC90, followed by moxifloxacin …

Buruli ulcer (Mycobacterium ulcerans infection) is a neglected tropical disease of skin and
subcutaneous tissue that can result in long-term cosmetic and functional disability. It is a …

ABSTRACT Introduction Pharmacological treatment of Buruli ulcer (Mycobacterium ulcerans
infection; BU) is highly effective, as shown in two randomized trials in Africa. Areas covered …